3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
prednylidene
1
methyl 5-aminolevulinate
1
gusacitinib
1
deltacortene
1
Specimen Handling
1
Sirolimus
1
Prednisone
1
Photochemotherapy
1
Nivolumab
1
Methods
1
Magnetic Resonance Spectroscopy
1
MAPRE1 protein, human
1
Ipilimumab
1
Interleukin-2
1
HhAntag691
1
CTLA-4 Antigen
1
Biopsy
1
BF-200 ALA
1
Arsenic Trioxide
1
Aminolevulinic Acid
1
5-aminolevulinic acid hexyl ester
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Basal Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled